E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the response, time to progression and survival in patients with colorectal cancer and mutation in the Pl3KCA treated with RAD001.
|
|
E.2.2 | Secondary objectives of the trial |
To fix the toxicity profile of this medicament in this kind of patients. To analyze the signalization pathways activated in this kind of patients. To fix the pharmadinamic effects of RAD001 on tumour biopsies and healthy tissue (skin) obtained from this kind of patients. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Signed IC 2. Cytological o pathological diagnosis of colorectal adenocarcinome, methastasic or refractary at least at one previous chemotheraphy and without effective chirurgical treatment. 3. At least for weeks since the last treatment at the beginning of the study. 4. Tumoural tissue available for mutation analysis, if not, the patient must permit to undergo to a biopsy. 5. Tumoural mutations in Pl3KCA gene. The mutations will be determinate by Kathleen Murphy at the Pathology department, Johns Hopkins Hospital. 6. Patients with biopsiable disease or agree to undergo to two biopsies (skin and tumour). 7. Age ≥ 18. 8. ECOG 0-2 (Karnofski ≥ 60 < 5 annexe 4) 9. Hope of life ≥ 12 weeks 10. Wright bone marrow function (7 days before starting the trial): leukocyte ≥ 3.0 x 109 /l RAN ≥ 1.5 x 109 /l platelets ≥ 100 x 109 /l 11. Wright hepatic function (7 days before starting the trial): seric bilirrubin inside normal limits, AST and ALT ≤ 2.5 x ULN 12. Wright renal function (7 days before starting the trial): seric creatinine inside normal limits or CrC ≥ 60 ml/min for those patients who has creatinine higher than normal limits. Total cholesterol triglycerides ≤ 2.5 ULN. 13. Scanner measurable disease, available for external revision with, at least one lesion ≥ 2cm (if helicoidal scanner used lesion ≥ 1cm) on a non radiated area. 14. RDA001 effects on foetus are unknowns so fertile women must use wright contraceptive methods (hormones, barrier, abstinence…) before and during the trial. If a woman knows or suspect his in pregnancy, she must immediately inform to the doctor
|
|
E.4 | Principal exclusion criteria |
1. Patients whose have received radio or chemotheraphy ( 6 weeks if treatment with nitrosourees or mitomicine C) on the previous 4 weeks before starting the trial. Also if they are not recovered from the adverse effects produced by previous oncologycal treatments. 2. Patients whose have had previous medicaments with a m-tor against target. 3. Patients with another experimental treatment. 4. Patients with cerebral metastasis. The prognostic for these patients is actually bad and the neurological symptomatology associated can make more laborious to evaluate the adverse effects associated to RAD001 5. Allergic to any substance similar to RAD001 6. Patients having forbidden treatments points 5.4.3 and 5.4.4 from the protocol. 7. Not controlled intercurrent diseases as hypertension, infections, cardiac insufficiency, pectoris angina, cardiac arrhythmias or psychiatric psychosocial diseases. 8. Antecedents or evidence of hereditary hemorrhagic diathesis or coagulophaty with hemorrhagic risk. 9. Patients can not receive anticoagulant treatment. It is allowed to receive prophylactic treatments (for example warfarin at low doses ) in case of venous or arterial reservoirs and only if TTPa, INR and TP requirements are ok. 10. Incapacity to take oral treatments or previous chirurgical treatments that affect to absortion or make necessary i.v. nutrition or parenteral lipid nutrition. 11. Women in pregnancy or in laitance period. A negative pregnancy test is required (in serum or orine) 7 days before starting the trial in all premenopausal women . RDA001 effects on foetus are unknowns, so women on laitance period must interrupt it before starting the treatment. 12. Patients with immune deficiencies have a bigger risk of lethal infections when mielosuppressor treatment is given. Patients with HIV and a retroviral therapy will be excluded from this trial because of possible medicamentous interactions with RAD001 or another medicaments administrated on this trial.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
free disease progression survival global survival clinical response |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | Information not present in EudraCT |
E.8.5 | The trial involves multiple Member States | Information not present in EudraCT |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Information not present in EudraCT |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
intololable toxicity full response disease pregresion |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |